X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GB1211, galectin-3 inhibitor, in combination with pembrolizumab is being investigated for the treatment of metastatic malignant melanoma and head and neck squamous cell carcinoma
Lead Product(s): GB1211,Pembrolizumab
Therapeutic Area: Oncology Product Name: GB1211
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2024
Details:
PAT-1251 (GB2064) is a potentially first-in-class, oral, lysyl oxidase-like 2 (LOXL2) inhibitor candidate, It is under phase 2 clinical development for the treatment of myelofibrosis.
Lead Product(s): GB2064
Therapeutic Area: Oncology Product Name: PAT-1251
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
GB0139 (olitigaltin) is an investigational small molecule inhibitor of galectin-3 that is administered as a once-daily inhalation via a generic dry powder inhaler. GB0139 is designed to specifically target galectin-3, a main regulator of the fibrosis cascade.
Lead Product(s): Olitigaltin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB0139
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2023
Details:
GB0139 is an investigational inhaled small molecule inhibitor of galectin-3 that is administered as a once-daily inhalation via a generic dry powder inhaler. GB0139 is designed to specifically target galectin-3, a main regulator of the fibrosis cascade.
Lead Product(s): Olitigaltin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB0139
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
GB2064, a first-in-class, oral, LOXL2 inhibitor candidate, is in development for the treatment of fibrotic diseases and cancer. LOXL2 is an enzyme that plays a key role in myelofibrosis and contributes to the fibrotic progression of the disease.
Lead Product(s): GB2064
Therapeutic Area: Oncology Product Name: GB2064
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
GB1211 demonstrated improvement and consistent signs of activity across biochemical liver function markers and markers of target engagement, apoptosis, and fibrosis, including reductions in galectin-3 (p<0.05) and CK-18 (M65) (p<0.002).
Lead Product(s): GB1211
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GB1211
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2022
Details:
GB1211 is an orally available and potent small molecule galectin-3 inhibitor. Initial target indications for GB1211 are liver cirrhosis, severe, progressive disease that ultimately leads to liver failure, and NSCLC.
Lead Product(s): GB1211,Atezolizumab
Therapeutic Area: Oncology Product Name: GB1211
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
Preclinical data has shown that GB1211 has the ability to reduce galectin-3-induced checkpoint inhibitor blockages, thus preventing galectin-3 from inducing checkpoint inhibitor resistance.
Lead Product(s): GB1211,Pembrolizumab
Therapeutic Area: Oncology Product Name: GB1211
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Providence Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 19, 2022
Details:
GB1211 is an orally available and potent small molecule galectin-3 inhibitor. Galecto’s initial target indications for GB1211 are liver cirrhosis, a severe, progressive disease that ultimately leads to liver failure, and non-small cell lung cancer.
Lead Product(s): GB1211
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GB1211
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
Four out of five evaluable myelofibrosis patients who received GB2064 monotherapy for least six months in MYLOX-1 trial , an improvement suggesting that GB2064 could impact the progression of disease and be disease modifying.
Lead Product(s): GB2064
Therapeutic Area: Oncology Product Name: GB2064
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
